Patents by Inventor Jaroslaw Mazurek

Jaroslaw Mazurek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF
    Publication number: 20210387993
    Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1, 5]pyrrolo[2,3 -d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
    Type: Application
    Filed: April 21, 2021
    Publication date: December 16, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
  • Morphic forms of trilaciclib and methods of manufacture thereof
    Patent number: 10988479
    Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 27, 2021
    Assignee: G1 Therapeutics, Inc.
    Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
  • Salts
    Patent number: 9546141
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: January 17, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • Salts
    Publication number: 20150126524
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Application
    Filed: September 12, 2014
    Publication date: May 7, 2015
    Applicant: SPROUT PHARMACEUTICALS, INC.
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-?-L-ribofuranosyl-1H-benzimidazole
    Patent number: 8541391
    Abstract: The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 24, 2013
    Assignee: ViroPharma Incorporated
    Inventors: Eugene C. Amparo, Cristina Stoica, Mihaela Pop, Jaroslaw Mazurek
  • NEW SALTS
    Publication number: 20120322810
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Application
    Filed: December 14, 2009
    Publication date: December 20, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • CRYSTALLINE PHASES OF 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-BETA-RIBOFURANOSYL-1H-BENZIMIDAZOLE
    Publication number: 20120277177
    Abstract: The invention relates to novel crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.
    Type: Application
    Filed: October 27, 2011
    Publication date: November 1, 2012
    Inventors: Eugene C. Amparo, Cristina Stoica, Mihaela Pop, Jaroslaw Mazurek
  • NEW SALTS
    Publication number: 20120122883
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Application
    Filed: December 14, 2009
    Publication date: May 17, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • NEW POLYMORPHS OF ETHYL 3-[(2-{[4-(HEXYLOXYCARBONYLAMINO-IMINO- METHYL)-PHENYLAMINO]-METHYL-1-METHYL-1H-BENZIMIDAZOLE-5-CARBONYL) -PYRIDIN-2-YL-AMINO]-PROPIONATE
    Publication number: 20100144796
    Abstract: The invention relates to new polymorphs of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate, the preparation thereof and the use thereof as pharmaceutical compositions.
    Type: Application
    Filed: November 15, 2007
    Publication date: June 10, 2010
    Applicant: Boehringer Ingelheim Pharma GMBH & CO.KG
    Inventors: Mihaela Pop, Jaroslaw Mazurek, Mimoun Lamkadmi
  • New Salts and Crystalline Salt Forms of an Indolinone Derivative
    Publication number: 20090318471
    Abstract: The present invention relates to new salts and crystalline salt forms of an indolinone derivative which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Application
    Filed: June 6, 2007
    Publication date: December 24, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Sieger, Werner Rall, Guenter Linz, Mihaela Pop, Jaroslaw Mazurek